Pepgen announces clearance by health canada of cta for pgn-edo51 to begin the phase 2 clinical trial, connect1-edo51, for the treatment of duchenne muscular dystrophy

- connect1-edo51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of pgn-edo51 in patients with mutations amenable to skipping exon 51 -
PEPG Ratings Summary
PEPG Quant Ranking